Dose Escalation Study to Evaluate the Safety and Tolerability of ELU001 in Pediatric Patients Who Have Relapsed and/or Refractory CBFA2T3::GLIS2 Positive Acute Myeloid Leukemia
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 主要终点
- Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ELU001
研究概览
简要总结
This research study was planned to focus on a rare type of acute myeloid leukemia (with the subtype CBFA2T3::GLIS2 that overexpresses folate receptor alpha (FRα) (a protein on the surface of leukemia cells)) that has relapsed or is refractory. Relapse means the cancer has come back after treatment. Refractory means the cancer does not respond to treatment.
详细描述
This study was planned as a Dose Escalation Safety Study to identify the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D). This study will also evaluate the tolerability of ELU001.
ELU001 is not a drug approved by the FDA (Food and Drug Administration) yet.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
盲法说明
Open Label
入排标准
- 年龄范围
- 1 Month 至 9 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet the following criteria to enroll in this study:
- •Infants (>1 month) and children (≤9 years) at time of enrollment.
- •Relapsed or refractory CBFA2T3::GLIS2 positive AML
- •CNS1 or CNS2 during screening
- •Performance Status: Lansky ≥ 50
- •Adequate Organ Function including liver, kidney, and heart
排除标准
- •Patients who meet any of the following are not eligible to enroll in this study:
- •CNS3 Disease
- •AML associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome or Diamond-Blackfan anemia, or bone marrow failure associated with inherited syndromes.
- •Acute promyelocytic leukemia.
- •Clinically significant active or chronic corneal disorder, particularly corneal epitheliopathy or any eye disorder that may predispose patient to this condition, or unable to comply with an age-appropriate ophthalmologic examination.
- •Prior treatment with folate receptor-targeting anti-cancer agent(s) ≤ 21 days (or 2 half-lives must have elapsed before enrollment, whichever is longer), or received investigational anti-cancer treatment ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, prior to starting study drug, whichever is shorter.
研究组 & 干预措施
ELU001
Dose Escalation: Escalating doses of ELU001
干预措施: ELU001 (Drug)
结局指标
主要结局
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ELU001
时间窗: 28 days
Establish the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ELU001 in pediatric patients with relapsed or refractory CBFA2T3::GLIS2 positive AML.
次要结局
- Evaluate preliminary anti-leukemic activity of ELU001(First dose of study drug until 42 days after last cycle.)
- Characterize the pharmacokinetics of ELU001(First dose of study drug until 42 days after last cycle.)
- Characterize the immunogenicity of ELU001(First dose of study drug until 42 days after last cycle.)